Avalyn Pharma Raises $175M In Series C Financing Round
Clinical stage biopharmaceutical company Avalyn said on Wednesday that it had closed its Series C financing round after securing $175 million from a group co-led by Perceptive Xontogeny Venture Funds, SR...To view the full article, register now.
Already a subscriber? Click here to view full article